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Abstract
Introduction: Acromegaly is caused due to the unregulated and 
sustained overproduction of growth hormone (GH). The majority of the 
cases are caused by autonomous secretion of GH from anterior pituitary 
tumours. Nonetheless, in <1% of the cases, the cause of autonomous 
secretion is secondary to ectopic GH-releasing hormone (GHRH) 
production. Bronchial carcinoids are the most common cause of ectopic 
GHRH production. Case Description: A 32-year-old female presented 
to the clinic with a history of cough, haemoptysis and undocumented 
weight loss for 4  years. Initial workup showed a large right main stem 
endobronchial mass. Transbronchial biopsy of the mass revealed a 
Grade I neuroendocrine tumour (NET). During NET workup, a large sellar 
mass was incidentally found on cross-sectional imaging. The hormonal 
profile revealed markedly elevated insulin-like growth factor-1 (IGF-1) 
and mildly raised prolactin. The magnetic resonance imaging (MRI) brain 
study revealed pituitary macroadenoma measuring 2 cm × 1.2 cm × 1.5 
cm. The patient underwent bronchial carcinoid tumour resection, which 
led to normalisation of serum IGF-1 and GH response to an oral glucose 
tolerance test. Subsequent MRI brain revealed complete resolution of 
previously noted sellar mass. Practical Implications: This case highlights 
the importance of differentiating acromegaly secondary to pituitary 
adenoma and ectopic acromegaly. This case emphasises the importance 
of keeping rare entities in the differential while assessing patients with 
pituitary macroadenoma. 
Key words: Acromegaly, bronchial tumour, ectopic acromegaly, 
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Introduction
Acromegaly is a chronic disorder caused by 
the hypersecretion of growth hormone (GH). 
Hypersecretion of GH leads to excess production 
of insulin-like growth factor-1 (IGF-1), leading to 
a multisystem disease characterised by somatic 
overgrowth, multiple comorbidities, premature 
mortality and physical disfigurement. The diagnosis 
of acromegaly should be suspected in individuals 
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who present with an enlarged jaw and enlarged 
hands and feet, which results in increasing shoe and 
ring size. The facial features become coarse with an 
enlarged nose, tongue and protrusion of the lower 
jaw. The rate of this change is so slow that only a 
few patients report a difference in their appearance. 
The prevalence of acromegaly is estimated to range 
from 38 to 80 cases per million population, and 
the annual incidence of new patients is 3–4 cases 
per million.[1]
In more than 95% of acromegaly patients, 
the underlying cause of GH hypersecretion 
is a pituitary adenoma. Other causes include 
excess secretion of GH-releasing hormone 
(GHRH) by hypothalamic tumours, ectopic GHRH 
secretion by neuroendocrine tumours (NET) 
and ectopic secretion of GH by NET.[2-4] Ectopic 
acromegaly caused by NET is caused by bronchial, 
pancreatic or gastrointestinal carcinoids,[5] with 
bronchial carcinoids being the most common 
cause (70%) followed by pancreatic islet cell 
carcinoids.[6] Bronchial NETs have been linked 
to hormone secretion in up to 30% of the cases. 
They can present with clinical features of Cushing’s 
syndrome, syndrome of inappropriate antidiuretic 
hormone secretion and acromegaly.[7]
This is a clinical case report of a patient with 
acromegaly due to paraneoplastic GHRH secretion 
mediated by a bronchial NET. The waiver of 
informed consent to publish this case report was 
obtained from the local Institutional Review Board 
(EX-24-10-19-02). 
Case Presentation
A 32-year-old female presented to the pulmonology 
clinic with cough, haemoptysis and weight loss for 
4 years. The computed tomography of the chest 
showed a large right main stem endobronchial 
mass. Transbronchial biopsy of the endobronchial 
mass revealed NET Grade I. During tumour staging 
workup, a large sellar mass was incidentally noted, 
which prompted a referral of the patient to the 
endocrine clinic for further assessment.
The endocrine evaluation revealed a pertinent 
history of amenorrhoea for 1 year. There was no 
history of galactorrhoea, headaches or visual 
disturbances. The patient did not report any 
changes in facial features. However, the family 
said that they noted a gradual change in her face’s 
shape. The clinical examination revealed subtle 
acromegalic features with prominent supraorbital 
ridges, enlarged nose and dry skin. The visual field 
examination of this patient was normal.
The magnetic resonance imaging (MRI) brain scan 
revealed pituitary macroadenoma measuring 2 cm 
× 1.2 cm × 1.5 cm extending into the suprasellar 
region, causing mild-to-moderate optic pathway 
compression [Figure  1]. The hormonal profile 
showed markedly elevated IGF-1 1018 ng/ml (115–
307 ng/ml) and mildly elevated prolactin levels 
136  ng/ml (1.9–25 ng/ml). The morning cortisol 
was 8.82 ug/dl (4.3–22.4 ug/dl), thyroid stimulating 
hormone (TSH) was 0.742 Uiu/ml (0.4–4 Uiu/ml), free 
thyroxine (free T4) was 1.5 ng/dl (0.89–1.76 ng/dl), 
follicle-stimulating hormone (FSH) was 3.15 mIU/mL 
(2.8–11.3 mIU/mL) and luteinising hormone (LH) 
was 0.559 mIU/mL (1.1–11.6 mIU/mL). An oral 
glucose tolerance test (OGTT) was not done at 
that time.
Figure 1: (a) Pre-operative contrast-enhanced computed 
tomography thorax in coronal view shows large 
endobronchial mass involving the right main stem 
bronchus and right lower lobar bronchus. (b) Sagittal 
post-gadolinium with fat saturation T1-weighted 
magnetic resonance image is showing pituitary 
macroadenoma measuring approximately 2 cm × 1.2 cm 
× 1.5 cm (anteroposterior × transverse × craniocaudal) 
occupying the sella and suprasellar cistern
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The coexistence of bronchial carcinoid and a 
pituitary lesion was suggestive of the presence of 
multiple endocrine neoplasia type 1 syndrome. 
The patient underwent an additional workup, 
which was representative of a raised serum 
parathyroid hormone level of 122.5 pg/mL 
(18.5–88 pg/mL), normal serum calcium level 
and 25-hydroxyvitamin-D level of 12.16 ng/mL 
(30–100 ng/mL). These results were conclusive 
for secondary hyperparathyroidism. Similarly, the 
CT triphasic abdomen scan did not reveal any 
pancreatic lesion.
Diagnosis and Management
Based on the history, clinical examination and 
radiological and pathological findings, a diagnosis 
of GH-secreting pituitary macroadenoma with 
bronchial carcinoid tumour was made. Following 
the discussion in a multidisciplinary team meeting, 
it was decided to proceed with right-sided 
pneumonectomy followed by reimaging the 
pituitary lesion and trans-sphenoidal resection.
The histopathology of the resected pulmonary 
mass revealed NET Grade II. The sample was 
positive for synaptophysin and anti-cytokeratin 
(CAM 5.2) stains. The proliferative ki67 index of 
the sample was 1%.
Four months post-surgery, the patient reported 
a normal menstrual cycle. Her hormonal profile 
normalised with IGF-1 levels of 116 ng/ml from 
1018 ng/ml (115 to 307 ng/ml), and prolactin 
levels reduced to 44.4 ng/ml from 136 ng/ml 
(1.9 to ng/ml). Morning cortisol, TSH, FT4 FSH and 
LH were all within the normal physiological range. 
The OGTT showed appropriate suppression of 
the GH. Repeat MRI brain revealed a significant 
interval decrease in the size of large pituitary 
macroadenoma with residual mass measuring 
1.6 cm × 1.3 cm × 0.8 cm [Figure 2a] against the 
initial measurement of 2 cm × 1.3 cm × 1.8 cm 
[Figure  2b]. This case was rediscussed in MDT. 
Based on the improving pathological markers and 
reducing the size of the pituitary adenoma, it was 
decided to use a wait-and-watch approach and 
defer the trans-sphenoidal resection.
Similarly, repeat MRI brain studies at 8 and 
18  months post-resection showed a significant 
shrinkage in tumour size [Figure 3]. At an 8-month 
follow-up, her IGF-1 levels were within the normal 
physiological range. At her 3-year follow-up, she 
remains well and asymptomatic.
Figure 2: (a) Coronal post-gadolinium with fat saturation 
T1-weighted magnetic resonance (MR) image shows 
sellar and suprasellar mass measuring approximately 
2 cm × 1.2 cm × 1.5 cm (anteroposterior × transverse 
× craniocaudal) and causing mild-to-moderate mass 
effect in the optic chiasm. (b) Coronal post-gadolinium 
T1-weighted MR image 4 months after the resection 
of the neuroendocrine tumour shows homogeneously 
enhancing large sellar mass with significant interval 
decrease in size compared to one in A. The residual 
enhancing tumour process currently measures 1.6 cm 
× 1.3 cm × 0.8 cm against the prior measurement of 
2 cm × 1.3 cm × 1.8 cm (anteroposterior × transverse 
× craniocaudal)
ba
Figure 3: Sagittal (a) and coronal (b) T1-weighted post-
gadolinium magnetic resonance images, 18 months 
post-resection of bronchial carcinoid tumour, show 
normalised pituitary glands with normal enhancement. 
There is complete resolution of previously noted mass in 
the pituitary gland before the resection of the right lung 
endobronchial tumour. No lesion is seen in the pituitary 
gland in the current study
ba
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Discussion
In this case, a large pituitary mass was found on 
early radiological imaging, which was initially 
considered a pituitary macroadenoma. However, 
resection of bronchial carcinoid tumour leads to 
normalisation of IGF-1 and GH levels on OGTT, 
with complete resolution of the enlarged pituitary 
gland in 18 months, suggesting the possibility 
of pituitary hyperplasia secondary to ectopic 
secretion of GHRH. Although GHRH levels were 
not available, the patient most likely suffered from 
a GHRH-secreting bronchial carcinoid. This was 
suggested by the presence of a histologically 
confirmed diagnosis of bronchial carcinoid tumour, 
and normalisation of serum IGF-1 level, and normal 
GH response following an OGTT post-complete 
resection of lung tumour.
NETs constitute 2% of all lung cancers.[7,8] One-
fourth of all NETs are located in the respiratory 
tract, making them the most frequent extraintestinal 
site for NET.[9] The reported annual incidence of 
pulmonary NET is about 1.35 in every 100,000 
cases.[10]
Patients with bronchial carcinoids usually have 
a tumour in proximal airways and present with 
cough, shortness of breath, wheeze, haemoptysis 
or recurrent chest infection secondary to bronchial 
obstruction.[11] The clinical features of patients with 
ectopic acromegaly are indistinguishable from GH-
secreting pituitary adenoma.[12] Similarly, serum 
GH and IGF-1 levels are elevated, and GH levels 
fail to suppress during OGTT in both acromegaly 
forms.[13] Plasma GHRH levels can differentiate 
between the two entities. It is normal or low in 
patients with pituitary driven acromegaly and 
elevated in ectopic GHRH-secreting tumours.[14] 
GHRH levels are not only a reliable marker for 
the diagnosis of ectopic acromegaly but it is also 
an indicator of disease activity following surgical 
treatment.[15]
Ectopic acromegaly and pituitary related 
acromegaly are challenging to differentiate on 
pituitary imaging. On pituitary imaging using MRI, 
findings vary from a normal pituitary gland to 
global pituitary hyperplasia or adenoma. In a case 
series of 63 patients with ectopic acromegaly, 12 
subjects had a normal brain MRI scan, 13 subjects 
had a pituitary adenoma and 38 cases had pituitary 
hyperplasia.[15]
This case report’s limitation is that the GHRH levels 
were not checked; neither GHRH staining was done 
on histopathology due to these modalities’ non-
availability in the country. However, normalisation 
of IGF-1 levels, suppression of GH on OGTT and 
complete resolution of pituitary mass following 
pneumonectomy suggest that ectopic GHRH 
production from the bronchial NET was the most 
likely diagnosis.
The overall prognosis for such patients is favourable, 
following surgical removal of the responsible 
tumour. In a series of 23 cases, a cure rate of 87% 
was reported after a median follow-up of 2 years,[16] 
while a French series of 21 cases stated a survival 
rate of 85% after a 5-year median follow-up.[17] 
This patient has had a successful outcome post-
resection of bronchial carcinoid tumour after a 
follow-up period of 3 years.
Ectopic acromegaly diagnosis is pivotal for the 
patient’s management, as complete excision of 
the responsible tumour is usually curative. This will 
avoid unnecessary interventions such as pituitary 
surgery. Ectopic acromegaly should be considered 
in patients with acromegaly clinical features 
where pituitary imaging does not demonstrate a 
discrete adenoma and in patients with resistant 
acromegaly despite multimodality treatment. This 
case adds to the existing literature of clinical cases 
of ectopic acromegaly, in particular, and highlights 
the diagnostic challenges encountered in clinical 
practice; it also highlights the importance of 
keeping ectopic origin in the differential diagnosis.
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